Tests a laser procedure to lower eye pressure in glaucoma
Tests a laser treatment for eye pressure in non-Caucasian adults with open angle glaucoma.
Plain-language title generated from the registry record
Registry title: Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma
Key facts
- Where
- Elkridge, United StatesSee the site
Where in United States
- Select Eye CareElkridge, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Select Eye Care
- Trial code
- NCT07147647
- Record updated
- 29 August 2025
- Original description
The goal of this clinical trial is to to evaluate how well Direct Selective Laser Trabeculoplasty (DSLT) lowers eye pressure in eyes of adult, non-Caucasian participants with primary open angle glaucoma. The main question it aims to answer is:Read full original descriptionShow less
Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Intraocular Pressure in Non-Caucasian Open Angle Glaucoma Patients
The goal of this clinical trial is to to evaluate how well Direct Selective Laser Trabeculoplasty (DSLT) lowers eye pressure in eyes of adult, non-Caucasian participants with primary open angle glaucoma. The main question it aims to answer is:
What is the washed out eye pressure (eye pressure when not on any glaucoma medications) of participants 6 months after the Direct Selective Laser Trabeculoplasty (DSLT) procedure compared to the washed out eye pressure of participants prior to the DSLT procedure.
Participants will:
Undergo the DSLT procedure in one or both eyes and visit the clinic 1 month, 3 months, and 6 months after the procedure to have their vision and eye pressure measured.
Inclusion: Adult patients of Black African descent scheduled to undergo DSLT treatment in one or both eyes; Diagnosis of mild to moderate primary open angle glaucoma (POAG); Mild to moderate POAG will be defined as Stage 2 or better of the Hodapp-Anderson-Parrish glaucoma staging system; Treatment naive or washed out IOP at time 0 ranging from ≥ 21 through 32 mm Hg.
Exclusion: Screened patients who were on IOP-lowering medications who did not successfully complete medication washout at the time of the procedure (time 0); Previous glaucoma surgeries/interventions:; Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt); Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases; Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator; Secondary glaucoma:; Subjects who are pregnant, breast-feeding, or intend to become pregnant during the study period as determined by verbal inquiry.